DexCom, Inc. vs iShares MSCI United Kingdom (FTSE) — how do they compare? DexCom, Inc. trades at $89.3 (market cap $33.79B), while iShares MSCI United Kingdom (FTSE) trades at $48.27. Which is the better fit depends on your goals.
| DXCM | EWU | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $48.68 |
52-Week Low | $54.84 | $40.90 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
EWU, the iShares MSCI United Kingdom ETF, trades at $48.38, down 0.23% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, facing mixed sentiment from oil price volatility and geopolitical tensions in the Middle East. Recent institutional activity includes Balefire LLC acquiring shares and Bank of America reducing its stake, reflecting divergent views on UK market exposure.
The outlook for EWU hinges on UK economic resilience amid political transitions and energy market fluctuations. Opportunities include diversification into developed market leaders, but risks involve sustained oil price pressures and regional instability. Analyst consensus remains neutral, with the ETF serving as a tactical play on British equities rather than a growth-centric investment.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.
Read more on EWU →